| Variable | HAQ <1.04 (N=71) |
HAQ ≥ 1.04 (N=28) |
p-Value |
|---|---|---|---|
| Age at first visit, years | 57 ± 13.1 | 67.5 ± 13.6 | 0.003 |
| Sex (female) | 50 (70.4%) | 26 (92.9%) | 0.017 |
| Duration of RA, years | 9.2 (6.3) | 10.2 (6.6) | 0.372 |
| RF positive status | 57 (83.8%) | 21 (77.8%) | 0.488 |
| ACPA positive status | 31 (58.5%) | 9 (42.9%) | 0.224 |
| ESR | 13.8 (11.0) | 17.0 (13.9) | 0.313 |
| CRP | 12.3 (26.8) | 15.8 (23.1) | 0.152 |
| Patient global VAS (mm), first visit | 22.4 ± 21.9 | 41.7 ± 21.9 | <0.001 |
| Pain VAS (mm), first visit | 29.8 ± 24.6 | 44.4 ± 22.6 | 0.008 |
| Tender joint count, max | 3.9 ± 5.6 | 7.3 ± 7.9 | 0.018 |
| Swollen joint count, max | 4.4 ± 5.2 | 6.8 ± 7.1 | 0.122 |
| Methotrexate use, ever | 60 (84.5%) | 28 (100%) | 0.027 |
| Other DMARD use, ever | 63 (88.7%) | 20 (71.4%) | 0.035 |
| Biologic use | 25 (35.2%) | 15 (53.6%) | 0.094 |
| Corticosteroid use | 20 (28.2%) | 17 (60.7%) | 0.003 |
| Any medication start/increase | 52 (73.2%) | 23 (82.1%) | 0.352 |
| Tramadol/opioid use | 25 (35.2%) | 17 (60.7%) | 0.021 |
| Antidepressant use | 14 (19.7%) | 13 (46.4%) | 0.007 |
| Anxiolytic use | 3 (4.2%) | 8 (28.6%) | 0.001 |
| Depression | 21 (29.6%) | 12 (42.9%) | 0.207 |
| Fibromyalgia | 5 (7.0%) | 3 (10.7%) | 0.546 |